A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
The rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells. In airway chips infected with influenza A, the co-administration of nafamostat with oseltamivir doubled the treatment-time window for oseltamivir. In chips infected with pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they can emulate human (patho)physiology in a more human-like environment49,51,55–57.”
From Human disease models in drug development (2023) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“the antimalarial drugs chloroquine and hydroxychloroquine, which received controversial attention during the COVID-19 pandemic, proved non-effective in a human lung-on-chip disease model, similar to clinical findings51.”
From Human disease models in drug development (2023) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“among eight drugs with dose-dependent inhibition of virus uptake in static Huh-7 cell monolayers, only three (amodiaquine, toremifene and clomiphene) proved effective in 3D OoC cultures51.”
From Human disease models in drug development (2023) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“amodiaquine (for example, NCT04532931, NCT04502342)51 and imatinib111 (for example, NCT04394416) have entered clinical trials.”
From Human disease models in drug development (2023) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · cited 5×
“5a) and shown in other pseudotyped SARS-CoV-2 viruses 20 .”
InfluentialA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 3×
“To initiate work immediately in our BSL2 laboratory and alleviate safety concerns, we designed SARS-CoV-2 pseudoparticles (SARS-CoV-2pp) that contain the SARS-CoV-2 spike (S) protein assembled onto luciferase reporter gene-carrying retroviral core particles 31 , based on the genome sequence of SARS-CoV-2 released in G…”
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 2×
“To initially assess whether Organ Chip technology 5–8 can be used to create a preclinical in vitro model for identification of new potential treatment strategies for pandemic respiratory viruses, we initially tested it against a drug that is used clinically for treatment of influenza A virus…”
Self-citationImbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · cited 1×
“All Raw data was processed as described elsewhere 63 .”
Self-citationNeutrophil extracellular traps in immunity and disease
Papayannopoulos, V. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.105 · Cited by 3,397
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · cited 7×
“The ability of SARS-CoV-2pp to efficiently infect human airway epithelial cells on-chip is consistent with our finding that these highly differentiated lung cells express high levels of its ACE2 receptor as well as TMPRSS2 (Fig.”
InfluentialOu, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · cited 1×
“Pseudotyped S protein-expressing viral particles faithfully reflect key aspects of native SARS-CoV-2 entry into host cells via binding to its ACE2 receptor 33 , and thus, they can be used to test potential entry inhibitors of SARS-CoV-2 20,31 .”
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501 · cited 3×
“ACE2 plays a central role in lung physiology and pathophysiology 19 , in addition to serving as the main receptor for SARS-CoV-2 that mediates its infection 20,21 .”
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,411
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318 · cited 3×
“This has resulted in equivocal results regarding drug efficacies and possible toxicity risks as in the case of hydroxychloroquine and chloroquine 1–4 ; thus, there is a great need to address this problem in a more systematic and human-relevant way.”
Research works printed but not linked: 1
- Chen, J. et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia (in Chinese). Chin. J. Infect. Dis. 38, E008–E008 (2020).
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Self-citationA guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
Organ-on-a-chip meets artificial intelligence in drug evaluation
Deng, S., Li, C., Cao, J., Cui, Z., Du, J., Fu, Z., Yang, H., & Chen, P. (2023) · Theranostics · doi:10.7150/thno.87266 · Cited by 260
“Recently, a vasculature OoC platform with innate immunity identified angiopoietin-1 derived peptide that can be used to therapeutic SARS-CoV-2 induced inflammation [155].”
BackgroundMethodInfluentialStrategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 224
Metadata
- Authors
- Si, L., Bai, H., Rodas, M., Cao, W., Oh, C. Y., Jiang, A., Moller, R., Hoagland, D., Oishi, K., Horiuchi, S., Uhl, S., Blanco-Melo, D., Albrecht, R. A., Liu, W.-C., Jordan, T., Nilsson-Payant, B. E., Golynker, I., Frere, J., Logue, J., Haupt, R., McGrath, M., Weston, S., Zhang, T., Plebani, R., Soong, M., Nurani, A., Kim, S. M., Zhu, D. Y., Benam, K. H., Goyal, G., Gilpin, S. E., Prantil-Baun, R., Gygi, S. P., Powers, R. K., Carlson, K. E., Frieman, M., tenOever, B. R., & Ingber, D. E.
- Affiliations
- Harvard University (US)
- Boston Children's Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Ingber, Donald E.
- ORCID
- Si, Longlong
- Bai, Haiqing
- Cao, Wuji
- Oh, Crystal Yuri
- Jiang, Amanda
- Moller, Rasmus
- Hoagland, Daisy
- Oishi, Kohei
- Horiuchi, Shu
- Uhl, Skyler
- Blanco-Melo, Daniel
- Albrecht, Randy A.
- Liu, Wen-Chun
- Jordan, Tristan
- Nilsson-Payant, Benjamin E.
- Golynker, Ilona
- Frere, Justin
- Logue, James
- Haupt, Robert
- McGrath, Marisa
- Weston, Stuart
- Zhang, Tian
- Plebani, Roberto
- Soong, Mercy
- Nurani, Atiq
- Benam, Kambez H.
- Goyal, Girija
- Gilpin, Sarah E.
- Gygi, Steven P.
- Powers, Rani K.
- Frieman, Matthew
- tenOever, Benjamin R.
- Ingber, Donald E.
- Venue
- Nature Biomedical Engineering
- Published
- 2021-05-03
- Volume
- 5
- Issue
- 8
- Pages
- 815-829
- ISSN
- 2157-846X (ISSN-L)
- PMC
- PMC8387338
- OpenAlex
- W3157288445
- Cited by
- 440
- References
- 65
- Citations by year
- 2026: 58 · 2025: 76 · 2024: 99 · 2023: 84 · 2022: 77 · 2021: 46
- FWCI
- 23.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Harvard University
- National Institutes of Health (NCATS 1-UH3-HL-141797-01)
- Centers for Disease Control and Prevention
- Defense Advanced Research Projects Agency (W911NF-12-2-0036, W911NF‐16‐C‐0050)
- Hansjörg Wyss Institute for Biologically Inspired Engineering, Harvard University
- National Heart, Lung, and Blood Institute (UG3HL141797, UH3HL141797)
- National Center for Advancing Translational Sciences (1-UH3-HL-141797-01)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Keywords
- human bronchial epithelium, pulmonary endothelium, antiviral drug repurposing, influenza A virus, SARS-CoV-2, nafamostat, oseltamivir, amodiaquine, hydroxychloroquine, organ-on-a-chip, prophylaxis, hamster challenge model, cytokine production, immune cell recruitment, viral infection modeling
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Testing, COVID-19 Drug Treatment, Animals, Antiviral Agents, Cell Line, Female, Cricetinae, Humans, Male, Green Fluorescent Proteins, Virus Internalization, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. https://app.cochat.ai/papers/10.1038/s41551-021-00718-9
- The paper
- Si, L., Bai, H., Rodas, M., Cao, W., Oh, C. Y., Jiang, A., Moller, R., Hoagland, D., Oishi, K., Horiuchi, S., Uhl, S., Blanco-Melo, D., Albrecht, R. A., Liu, W.-C., Jordan, T., Nilsson-Payant, B. E., Golynker, I., Frere, J., Logue, J., . . . Ingber, D. E. (2021). A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-021-00718-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.